164 related articles for article (PubMed ID: 38251610)
1. Artificial intelligence and high-dimensional technologies in the theragnosis of systemic lupus erythematosus.
Yaung KN; Yeo JG; Kumar P; Wasser M; Chew M; Ravelli A; Law AHN; Arkachaisri T; Martini A; Pisetsky DS; Albani S
Lancet Rheumatol; 2023 Mar; 5(3):e151-e165. PubMed ID: 38251610
[TBL] [Abstract][Full Text] [Related]
2. [Research progress in systemic lupus erythematosus from 2021 to 2022].
Li YZ; Wu XC
Zhongguo Dang Dai Er Ke Za Zhi; 2023 Aug; 25(8):785-790. PubMed ID: 37668024
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic and prognostic tests in systemic lupus erythematosus.
Vasquez-Canizares N; Wahezi D; Putterman C
Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):351-363. PubMed ID: 29224677
[TBL] [Abstract][Full Text] [Related]
4. Omics studies: their use in diagnosis and reclassification of SLE and other systemic autoimmune diseases.
Teruel M; Chamberlain C; Alarcón-Riquelme ME
Rheumatology (Oxford); 2017 Apr; 56(suppl_1):i78-i87. PubMed ID: 28339517
[TBL] [Abstract][Full Text] [Related]
5. The applied basic research of systemic lupus erythematosus based on the biological omics.
Sui W; Hou X; Che W; Yang M; Dai Y
Genes Immun; 2013 Apr; 14(3):133-46. PubMed ID: 23446742
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Heterogeneity in Systemic Lupus Erythematosus for New Therapies.
Allen ME; Rus V; Szeto GL
Trends Mol Med; 2021 Feb; 27(2):152-171. PubMed ID: 33046407
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial.
Navarra SV; Guzmán RM; Gallacher AE; Hall S; Levy RA; Jimenez RE; Li EK; Thomas M; Kim HY; León MG; Tanasescu C; Nasonov E; Lan JL; Pineda L; Zhong ZJ; Freimuth W; Petri MA;
Lancet; 2011 Feb; 377(9767):721-31. PubMed ID: 21296403
[TBL] [Abstract][Full Text] [Related]
8. Systemic lupus erythematosus diagnostics in the 'omics' era.
Arriens C; Mohan C
Int J Clin Rheumtol; 2013 Dec; 8(6):671-687. PubMed ID: 24860621
[TBL] [Abstract][Full Text] [Related]
9. The pathogenesis of systemic lupus erythematosus: Harnessing big data to understand the molecular basis of lupus.
Catalina MD; Owen KA; Labonte AC; Grammer AC; Lipsky PE
J Autoimmun; 2020 Jun; 110():102359. PubMed ID: 31806421
[TBL] [Abstract][Full Text] [Related]
10. Advances in applying of multi-omics approaches in the research of systemic lupus erythematosus.
Song W; Tang D; Chen D; Zheng F; Huang S; Xu Y; Yu H; He J; Hong X; Yin L; Liu D; Dai W; Dai Y
Int Rev Immunol; 2020; 39(4):163-173. PubMed ID: 32138562
[TBL] [Abstract][Full Text] [Related]
11. Belimumab: review of use in systemic lupus erythematosus.
Boyce EG; Fusco BE
Clin Ther; 2012 May; 34(5):1006-22. PubMed ID: 22464040
[TBL] [Abstract][Full Text] [Related]
12. Increased levels of anti-dsDNA antibodies in immune complexes before treatment with belimumab associate with clinical response in patients with systemic lupus erythematosus.
Sohrabian A; Parodis I; Carlströmer-Berthén N; Frodlund M; Jönsen A; Zickert A; Sjöwall C; Bengtsson AA; Gunnarsson I; Rönnelid J
Arthritis Res Ther; 2019 Nov; 21(1):259. PubMed ID: 31783909
[TBL] [Abstract][Full Text] [Related]
13. Systemic lupus in the era of machine learning medicine.
Zhan K; Buhler KA; Chen IY; Fritzler MJ; Choi MY
Lupus Sci Med; 2024 Mar; 11(1):. PubMed ID: 38443092
[TBL] [Abstract][Full Text] [Related]
14. Epigenetics in the treatment of systemic lupus erythematosus: potential clinical application.
Guo Y; Sawalha AH; Lu Q
Clin Immunol; 2014 Nov; 155(1):79-90. PubMed ID: 25218424
[TBL] [Abstract][Full Text] [Related]
15. Emerging Molecular Markers Towards Potential Diagnostic Panels for Lupus.
Tan G; Baby B; Zhou Y; Wu T
Front Immunol; 2021; 12():808839. PubMed ID: 35095896
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of belimumab combined with rituximab in severe systemic lupus erythematosus: study protocol for the phase 3, multicenter, randomized, open-label Synbiose 2 trial.
van Schaik M; Arends EJ; Soonawala D; van Ommen E; de Leeuw K; Limper M; van Paassen P; Huizinga TWJ; Toes REM; van Kooten C; Rotmans JI; Rabelink TJ; Teng YKO
Trials; 2022 Nov; 23(1):939. PubMed ID: 36371234
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of belimumab after B cell depletion therapy in systemic LUPUS erythematosus (BEAT-LUPUS) trial: statistical analysis plan.
Muller P; Chowdhury K; Gordon C; Ehrenstein MR; Doré CJ
Trials; 2020 Jul; 21(1):652. PubMed ID: 32677992
[TBL] [Abstract][Full Text] [Related]
18. Study of Anti-Malarials in Incomplete Lupus Erythematosus (SMILE): study protocol for a randomized controlled trial.
Olsen NJ; James JA; Arriens C; Ishimori ML; Wallace DJ; Kamen DL; Chong BF; Liao D; Chinchilli VM; Karp DR
Trials; 2018 Dec; 19(1):694. PubMed ID: 30572906
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of belimumab in systemic lupus erythematosus patients with severe lupus nephritis requiring renal replacement therapy.
Liu D; Zhou Q; Wang D; Qu Y; Guo Q; Wen J; Yu Q; Ai J
Lupus; 2022 Oct; 31(12):1456-1467. PubMed ID: 35960182
[TBL] [Abstract][Full Text] [Related]
20. Clinical efficacy of belimumab in central nervous system demyelinating syndromes with systemic lupus erythematosus: A case series.
Liu Y; Fan Q; Jia C; Wan Q; Yang H
Medicine (Baltimore); 2023 Jun; 102(25):e34079. PubMed ID: 37352070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
